teniposide
Trade name: vumon
Small moleculeapprovedOrphan Drug FDA
Approved
Jul 14, 1992
Teniposide is an inhibitor of topoisomerase II with anti-cancer activity. The drug was approved by FDA under the name Vumon for the treatment of children with acute lymphoblastic leukemia. — NCATS
Clinical trial activity
15 trials · 12 clinical orgs · 2 marketing orgs
Phase 1
1
Phase 2
7
Phase 3
2
Phase 4
7
Earliest trial started Jan 1, 1993 (NCT00002531)
Timeline
1980s
- Nov 1, 1984
Orphan Drug Designation
1990s
- Jul 14, 1992
Bristol-Myers Squibb — Earliest FDA Approval
- Jul 14, 1992
Hq Speciality Pharma — NDA Secondary Org
- Jul 14, 1992
Bristol-Myers Squibb — NDA Organization
- Jan 1, 1993
Earliest Phase 2 Sponsor(trial)
- Jan 1, 1997
Earliest Phase 3 Sponsor(trial)
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Leukemia · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 4
- Lymphohistiocytosis, Hemophagocytic · Phase 3
- Lymphoma · Phase 4
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 4
- Recurrence · Phase 3
Mechanism of action
- DNA topoisomerase IIINHIBITOR
DNA topoisomerase II inhibitor
Approval history
- approvedPriority reviewJul 14, 1992
Chemistry & pharmacology
Loading structure…
SMILES
COC1=CC(=CC(OC)=C1O)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](O[C@@H]4O[C@@H]5CO[C@H](O[C@H]5[C@H](O)[C@H]4O)C6=CC=CS6)C7=C2C=C8OCOC8=C7- Mol. weight
- 656.654 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Black box warning
Sources
- WikipediaTeniposide ↗
- NCATS957E6438QA ↗
- ChEMBLCHEMBL452231 ↗
Also known as
- 4'-demethylepipodophyllotoxin 9-(4,6-o-(r)-2-thenylidene-beta-d-glucopyranoside)
- 4'-demethylepipodophyllotoxin 9-(4,6-o-(r)-2-thenylidene-beta-d-glucopyranoside)
- 4'-demethylepipodophyllotoxin 9-(4,6-o-(r)-ethylidene-beta-d-glucopyranoside)
- 4'-demethylepipodophyllotoxin 9-(4,6-o-(r)-ethylidene-beta-d-glucopyranoside)
- epidophyllotoxin
- epidophyllotoxin
- teniposid
- teniposid
- teniposide
- teniposide
- teniposide
- teniposide
- teniposide
- teniposide
- teniposide
- teniposide
- teniposide
- teniposide
- teniposide
- téniposide
- téniposide
- teniposido
- teniposido
- teniposidum
- teniposidum
- tenoposide
- vm26
- vm26
- vm-26
- vm-26
- vumon
- vumon
- vumon
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06038422 | Phase 3 | Sep 15, 2023 | Capital Medical University |
| NCT01700946 | Phase 2 | Apr 15, 2013 | Assisi Foundation, Cookies for Kids' Cancer, St. Jude Children's Hospital |
| NCT01960192 | Phase 4 | Jun 1, 2012 | Zhengzhou University |
| NCT00199004 | Phase 4 | Apr 1, 2004 | J. W. Goethe University |
| NCT00186875 | Phase 2 | Nov 1, 2003 | St. Jude Children's Hospital |
| NCT00198991 | Phase 4 | Apr 1, 2003 | Deutsche Krebshilfe e.V., German Federal Ministry of Education and Research, J. W. Goethe University |
| NCT00853008 | Phase 4 | Jan 1, 2003 | PETHEMA Foundation |
| NCT00343369 | N/A | Jan 1, 2003 | University of Hamburg |
| NCT00199056 | Phase 4 | Oct 1, 1999 | J. W. Goethe University |
| NCT00004231 | Phase 2 | Oct 1, 1999 | National Cancer Institute (NCI), Northwestern University |
| NCT00004916 | Phase 1/Phase 2 (Phase 2) | Feb 1, 1999 | National Cancer Institute (NCI), Northwestern University |
| NCT00199095 | Phase 4 | Feb 1, 1997 | J. W. Goethe University |
| NCT00187083 | Phase 3 | Feb 1, 1997 | St. Jude Children's Hospital |
| NCT00199069 | Phase 4 | Apr 1, 1993 | Deutsche Krebshilfe e.V., J. W. Goethe University |
| NCT00002531 | Phase 2 | Jan 1, 1993 | J. W. Goethe University |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| J. W. Goethe University | Academic/Hospital | 6 | 6 | 2 | 1993 |
| St. Jude Children's Hospital | Academic/Hospital | 3 | 3 | 2 | 1997 |
| Deutsche Krebshilfe e.V. | Academic/Hospital | 2 | 0 | 1 | 1993 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 1999 |
| Northwestern University | Academic/Hospital | 2 | 2 | 1 | 1999 |
| Assisi Foundation | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Cookies for Kids' Cancer | Academic/Hospital | 1 | 0 | 1 | 2013 |
| German Federal Ministry of Education and Research | Government | 1 | 0 | 1 | 2003 |
| PETHEMA Foundation | Academic/Hospital | 1 | 1 | 1 | 2003 |
| University of Hamburg | Academic/Hospital | 1 | 1 | 1 | 2003 |
| Zhengzhou University | Academic/Hospital | 1 | 1 | 1 | 2012 |
12 organizations
Page 1 / 1
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bristol-Myers Squibb | For profit | NDA | Jul 14, 1992 |
| Hq Speciality Pharma | For profit | NDA2 | Jul 14, 1992 |